- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Barco gets go-ahead for workstation display
Barco gets go-ahead for workstation displayBelgian firm Barco Display Systems has gained Food and Drug Administration 510(k) clearance for its MWD321 1600 x 1200 medical workstation display. The TrueGrey MWD321 monitor provides multimodality
Barco gets go-ahead for workstation display
Belgian firm Barco Display Systems has gained Food and Drug Administration 510(k) clearance for its MWD321 1600 x 1200 medical workstation display. The TrueGrey MWD321 monitor provides multimodality support and is designed for a variety of medical imaging applications requiring accurate gray-scale images as well as long-term color stability, according to the Kortrijk, Belgium-based firm. The monitor also features what the company calls a clear base/blue base medical film simulation function, which allows the user to see diagnostic information displayed in his or her preferred viewing mode.
- Search again
- Homepage
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
